Autologous DC Therapy — Competitive Intelligence Brief

Autologous DC Therapy (Autologous DC Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cell therapy. Area: Oncology.

phase 1 cell therapy Oncology Biologic

Target snapshot

Autologous DC Therapy (Autologous DC Therapy) — Diakonos Oncology Corporation. Autologous dendritic cells are loaded with tumor antigens to stimulate a patient-specific immune response against cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Autologous DC Therapy TARGET	Autologous DC Therapy	Diakonos Oncology Corporation	phase 1	cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Cord Blood Cell	Cord Blood Cell	China Spinal Cord Injury Network	marketed	Cell therapy
ACP	ACP	Istituto Ortopedico Rizzoli	marketed	Cell therapy / Regenerative medicine product
PCRA (Intermittent injection)	PCRA (Intermittent injection)	Örebro University, Sweden	marketed	Cancer vaccine / Autologous cell therapy
Licartin and CIK	Licartin and CIK	Tianjin Medical University Cancer Institute and Hospital	marketed	Monoclonal antibody (Licartin); Adoptive cell therapy (CIK)	HAb18G/CD147 antigen (Licartin); Multiple (CIK cells)
MC	MC	Aivita Biomedical, Inc.	marketed	Mesenchymal stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cell therapy class)

1. Lisata Therapeutics, Inc. · 2 drugs in this class
2. Diakonos Oncology Corporation · 1 drug in this class
3. Lineage Cell Therapeutics, Inc. · 1 drug in this class
4. Steminent Biotherapeutics Inc. · 1 drug in this class